
In re: Glucksmann et al. Appl. No.: 09/495,823 Filed: January 31, 2000 Page 2

, or, or a complement thereof;
c) a nucleic acid molecule which encodes a polypeptide comprising the
amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence
encoded by the cDNA insert of any of the plasmids deposited with ATCC as
Patent Deposit Numbers,, or;
d) a nucleic acid molecule which encodes a fragment of a polypeptide
comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid
sequence encoded by the cDNA insert of any of the plasmids deposited with
ATCC as Patent Deposit Numbers,, or, wherein the
fragment comprises at least 12 contiguous amino acids of SEQ ID NO:1, 3, 5, or
7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids
deposited with ATCC as Patent Deposit Numbers,, or;
and
e) a nucleic acid molecule which encodes a naturally occurring allelic variant
of a polypeptide comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7,
or an amino acid sequence encoded by the cDNA insert of any of the plasmids
deposited with ATCC as Patent Deposit Numbers,, or,
wherein the nucleic acid molecule hybridizes to a nucleic acid molecule
comprising SEQ ID NO:2, 4, 6, or 8, or a complement thereof under stringent
conditions.
The isolated nucleic acid molecule of claim 243, which is selected from the group
a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID
NO:2, 4, 6, or 8, the cDNA insert of any one the plasmids deposited with ATCC
as Patent Deposit Numbers,, or, or a complement
thereof; and


244.

consisting of:

243.





Page 3



the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit

Numbers \_\_\_\_, \_\_\_\_, or \_\_\_\_;








1

In re: Glucksmann *et al.* Appl. No.: 09/495,823 Filed: January 31, 2000



- 255. The method of claim 252 wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:1, 3, 5, or 7.
- 256. A method for detecting the presence of a polypeptide of claim 250 in a sample, comprising:
  - a) contacting the sample with a compound which selectively binds to a polypeptide of claim 250; and
  - b) determining whether the compound binds to the polypeptide in the sample.
- 257. The method of claim 256, wherein the compound which binds to the polypeptide is an antibody.
- 258. A kit comprising a compound which selectively binds to a polypeptide of claim 250 and instructions for use.



In re: Glucksmann *et al.* Appl. No.: 09/495,823 Filed: January 31, 2000

- 259. A method for detecting the presence of a nucleic acid molecule of claim 243 in a sample, comprising the steps of:
  - a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
  - b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
- 260. The method of claim 259, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
- 261. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 243 and instructions for use.
- 262. A method for identifying a compound which binds to a polypeptide of claim 250 comprising the steps of:
  - a) contacting a polypeptide, or a cell expressing a polypeptide of claim 250 with a test compound; and
  - b) determining whether the polypeptide binds to the test compound.
- 263. The method of claim 262, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:
  - a) detection of binding by direct detecting of test compound/polypeptide binding;
  - b) detection of binding using a competition binding assay;
  - c) detection of binding using an assay for GPCR-like-mediated signal transduction.



1

In re: Glucksmann *et al*. Appl. No.: 09/495,823 Filed: January 31, 2000

- 264. A method for modulating the activity of a polypeptide of claim 250 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 250 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.
- 265. A method for identifying a compound which modulates the activity of a polypeptide of claim 250, comprising:
  - a) contacting a polypeptide of claim 250 with a test compound; and
  - b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.
- 266. A method for identifying an agent that modulates the level of expression of a nucleic acid molecule of claim 243 in a cell, said method comprising contacting said agent with the cell expressing said nucleic acid molecule such that said level of expression of said nucleic acid molecule can be modulated in said cell by said agent and measuring said level of expression of said nucleic acid molecule.
- 267. A method for modulating the level of expression of a nucleic acid molecule of claim 243, said method comprising contacting said nucleic acid molecule with an agent under conditions that allow the agent to modulate the level of expression of the nucleic acid molecule.
- 268. A pharmaceutical composition containing any of the polypeptides in claim 250 in a pharmaceutically acceptable carrier.--